Effects of ranibizumab on TGF-β1 and TGF-β2 production by human Tenon's fibroblasts: An in vitro study

Noh SM 1 , Abdul Kadir SH 1 , Crowston JG 2 , Subrayan V 3 , Vasudevan S 1

Affiliations 

  • 1 Faculty of Medicine, Brain and Neuroscience Communities of Research, Universiti Teknologi MARA (UiTM) Shah Alam, Selangor, Malaysia
  • 2 Centre for Eye Research Australia, the University Of Melbourne, Melbourne, VIC, Australia
  • 3 Department of Ophthalmology, Faculty of Medicine, University of Malaya, Malaysia
Mol Vis, 2015;21:1191-200.
PMID: 26539031

Abstract

Inhibiting exaggerated wound healing responses, which are primarily mediated by human Tenon's fibroblast (HTF) migration and proliferation, has become the major determining factor for a successful trabeculectomy. Antivascular endothelial growth factor (anti-VEGF) has showed promising results as a potential antifibrotic candidate for use concurrently in trabeculectomy. Preliminary cohort studies have revealed improved bleb morphology following trabeculectomy augmented with ranibizumab. However, the effects on HTFs remain unclear. This study was conducted to understand the effects of ranibizumab on transforming growth factor (TGF)-β1 and transforming growth factor (TGF)-β2 expression by HTFs.

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

MeSH terms
Similar publications